Skin cancer vaccine closer to approval
Skin cancer vaccine closer to approval
Vaccine boosts five-year survival by 30%
AVAX Technologies in Kansas City, MO, will begin marketing M-VAX, an autologous cancer vaccine for Stage 3 metastatic melanoma, next year in Australia. The company recently announced that it is also expected to be available for commercial use soon in The Nether lands, Germany, and Japan.
M-VAX is the first of several autologous cell vaccines based on AVAX’s proprietary AC Vaccine technology. To date, more than 350 patients have been treated with M-VAX on an outpatient basis. The vaccine has shown promise as an adjuvant therapy in Stage 3 melanoma patients, with overall five-year survival of 55%, compared with a historical five-year survival rate of 22% with surgery alone.
M-VAX received orphan drug status early this year and is currently being evaluated in a multi-center registration trial in the United States.
The vaccine is made from a patient’s own cancer cells by modifying the tumor cells with a molecule called a "hapten." That process, which is known as "haptenization," alters the tumor cells and makes them appear foreign to the patient’s immune system. When the hapten-modified cells are reinjected into patients, they stimulate the immune system to recognize the cancer cells and destroy them.
AVAX also is testing vaccines for advanced ovarian cancer and post-surgical treatment of breast cancer.
(For more information, visit www. avax-tech. com.)
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.